KRAS and neoplasm: The identical KRAS G12C and TP53 F338fs variants that appeared in patients’ tumours and cfDNA before therapy were also detected after the emergence of resistance along with the introduction of 10 unique mutations affecting the four RAS/MAPK subunits, namely KRAS, NRAS, BRAF, and MAPK1.